Steven A. Boyd
VenatoRx Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Renin-Angiotensin System Studies, Pancreatic function and diabetes, Receptor Mechanisms and Signaling, Hormonal Regulation and Hypertension, Metabolism, Diabetes, and Cancer
Most-Cited Works
- → 2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722(1996)110 cited
- → Identification of Benzoxazin-3-one Derivatives as Novel, Potent, and Selective Nonsteroidal Mineralocorticoid Receptor Antagonists(2011)109 cited
- → Identification of Novel Inhibitors of Urokinase via NMR-Based Screening(2000)79 cited
- → Palladium-catalyzed synthesis of macrocycles. A total synthesis of (-)-aspochalasin B(1989)63 cited
- → Selective Inhibition of ICAM-1 and E-Selectin Expression in Human Endothelial Cells. 2. Aryl Modifications of 4-(Aryloxy)thieno[2,3-c]pyridines with Fine-Tuning at C-2 Carbamides(2001)56 cited
- → Synthesis, in vitro and in vivo activity of thiamine antagonist transketolase inhibitors(2007)56 cited
- → Discovery of Inhibitors of Cell Adhesion Molecule Expression in Human Endothelial Cells. 1. Selective Inhibition of ICAM-1 and E-Selectin Expression(2001)52 cited
- → Discovery of VNRX-7145 (VNRX-5236 Etzadroxil): An Orally Bioavailable β-Lactamase Inhibitor for Enterobacterales Expressing Ambler Class A, C, and D Enzymes(2021)41 cited
- → Non-charged thiamine analogs as inhibitors of enzyme transketolase(2007)40 cited
- → C-Terminal modifications of nonpeptide renin inhibitors: improved oral bioavailability via modification of physicochemical properties(1992)39 cited